DDInter512 DDInter1676
Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated. The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound. This allows less frequent dosing and a lower daily dose with improvement in tolerability. Decreased plasma fluctuations of deutetrabenazine due to attenuated metabolism may explain a lower incidence of adverse reactions associated with deutetrabenazine. Deutetrabenazine is a racemic mixture containing RR-Deutetrabenazine and SS-Deutetrabenazine [FDA Label]. Huntington's disease (HD) is a hereditary, progressive neurodegenerative disorder characterized by motor dysfunction,
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Deutetrabenazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Deutetrabenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Deutetrabenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fedratinib
Deutetrabenazine {u} may lead to a major life threatening interaction when taken with {v} Dacomitinib
Deutetrabenazine {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Deutetrabenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Deutetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin
Deutetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Deutetrabenazine may lead to a major life threatening interaction when taken with Dacomitinib
Deutetrabenazine may lead to a major life threatening interaction when taken with Macimorelin